Biểu đồ giá cổ phiếu LYRA
LYRA Dự đoán giá cổ phiếu
Lyra Therapeutics Inc
$0
0%
$0
Khi đóng cửa: May 12, 16:00:00 GMT-4
$0
0%
$0
Phiên sau giờ: May 12, 20:00:00 GMT-4
Quay lại
Lyra Therapeutics Inc (LYRA) Dự đoán giá cổ phiếu
Thống kê chính
Giá đóng cửa trước
--
Giá mở cửa
--
Phạm vi ngày
-
Phạm vi 52 tuần
-
Khối lượng
--
Khối lượng trung bình
--
Tỷ suất cổ tức
--
EPS (TTM)
--
Vốn hóa thị trường
--
LYRA là gì?
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2020-05-01. The firm is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The firm is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).
